Aug. 5 at 11:55 AM
$ELAN Elanco raises FY26 adjusted EPS view to
$1.10-
$1.16 from
$1.03-
$1.09
Consensus
$1.07. Raises FY26 revenue view to
$5.09B-
$5.14B from
$5.01B-
$5.09B, consensus
$5.05B. Raises FY26 adjusted EBITDA view to
$1.01B-
$1.04B from
$975M-
$1.01B. "Our strong second quarter performance allows us to both raise our full-year outlook and continue to invest in our innovation products, driving market share gains while expanding the total animal health industry," said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. "Our faster than expected margin expansion includes good early progress on our Elanco Ascend productivity initiatives, on track to
$200 million to
$250 million in adjusted EBITDA net savings by 2030. With a net leverage ratio of 3.1x at quarter-end, also faster than expected, we are closing in on our target of reaching below 3x next year, a key milestone that will unlock greater capital allocation flexibility."
